ATE404691T1 - Pyruvat-kinase als einem neuen zielmolekül - Google Patents

Pyruvat-kinase als einem neuen zielmolekül

Info

Publication number
ATE404691T1
ATE404691T1 AT02748716T AT02748716T ATE404691T1 AT E404691 T1 ATE404691 T1 AT E404691T1 AT 02748716 T AT02748716 T AT 02748716T AT 02748716 T AT02748716 T AT 02748716T AT E404691 T1 ATE404691 T1 AT E404691T1
Authority
AT
Austria
Prior art keywords
target molecule
new target
pyruvate kinase
pyruvate
kinase
Prior art date
Application number
AT02748716T
Other languages
English (en)
Inventor
Axel Ullrich
Attila Stetak
Gyorgy Keri
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE404691T1 publication Critical patent/ATE404691T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02748716T 2001-05-23 2002-05-23 Pyruvat-kinase als einem neuen zielmolekül ATE404691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112601 2001-05-23

Publications (1)

Publication Number Publication Date
ATE404691T1 true ATE404691T1 (de) 2008-08-15

Family

ID=8177529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748716T ATE404691T1 (de) 2001-05-23 2002-05-23 Pyruvat-kinase als einem neuen zielmolekül

Country Status (10)

Country Link
US (2) US20040152648A1 (de)
EP (2) EP1990422A1 (de)
AT (1) ATE404691T1 (de)
AU (1) AU2002319180B2 (de)
CA (1) CA2448165A1 (de)
DE (1) DE60228233D1 (de)
DK (1) DK1390525T3 (de)
ES (1) ES2312595T3 (de)
PT (1) PT1390525E (de)
WO (1) WO2002095063A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016646A2 (en) * 2002-08-12 2004-02-26 Amynon Bio Tech Gmbh Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
EP1572118A4 (de) * 2002-12-20 2010-07-14 Millennium Pharm Inc Verfahren und zusammensetzungen zur behandlung von krebs mit 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
WO2006055880A2 (en) * 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
WO2006065967A2 (en) * 2004-12-15 2006-06-22 General Atomics Allosteric enzyme coupled immunoassay (aecia)
WO2009025781A1 (en) * 2007-08-16 2009-02-26 Beth Israel Deaconess Medical Center Activators of pyruvate kinase m2 and methods of treating disease
ES2620634T3 (es) 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法
PL2427441T3 (pl) 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Aktywatory PKM2 do stosowania w leczeniu raka
DK2448581T3 (en) 2009-06-29 2017-03-13 Agios Pharmaceuticals Inc Therapeutic compositions and methods for their applications
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2525790B1 (de) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2542267A4 (de) 2010-03-05 2014-09-17 Univ Columbia Die rna-bindeproteine hnrnpa1, hnrnpa2 und ptb hemmende rnas und verwendungen davon
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
WO1998035032A2 (en) * 1997-02-11 1998-08-13 The Regents Of The University Of California Methods of inducing cell cycle stasis
US7074895B2 (en) * 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
US5948628A (en) * 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay

Also Published As

Publication number Publication date
DE60228233D1 (de) 2008-09-25
EP1390525B1 (de) 2008-08-13
EP1390525A1 (de) 2004-02-25
EP1390525B8 (de) 2009-03-04
WO2002095063A1 (en) 2002-11-28
US20080021116A1 (en) 2008-01-24
PT1390525E (pt) 2008-11-25
US20040152648A1 (en) 2004-08-05
AU2002319180B2 (en) 2007-07-05
CA2448165A1 (en) 2002-11-28
ES2312595T3 (es) 2009-03-01
DK1390525T3 (da) 2008-12-08
EP1990422A1 (de) 2008-11-12

Similar Documents

Publication Publication Date Title
DE60228233D1 (de) Pyruvat-kinase als einem neuen zielmolekül
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB0325956D0 (en) Novel compounds
NO20063624L (no) FC region varianter
SE0202838D0 (sv) Chemical compounds
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
TW200407305A (en) Novel compounds
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
BR0316421A (pt) Composição farmacêutica compreendendo micropartìculas de octreotìdeo
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
NO20033401L (no) Kjemiske forbindelser
WO2002062297A3 (en) Methods and compositions for modulating gluconeogenesis using pgc-1
SE0301798D0 (sv) New use IV

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390525

Country of ref document: EP

REN Ceased due to non-payment of the annual fee